Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 13Neoplasm Metastasis 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Endometrial Neoplasms 2Solid Tumors 1PIK3CA-Mutated Cancers 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Metastatic Castration-Resistant Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Irinotecan 7Bevacizumab 7Injections 6Cetuximab 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5Capecitabine 5tocilizumab 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3pazopanib 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Tumors × inavolisib × Clear all
NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡